Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 422 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Today is Random Acts of Kindness Day February 17, 2021 ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025 May 7, 2025 Higher Risk of Heart Failure Seen in Some Cancers March 26, 2018 4 Tips from Oncology Dietitians for Healthier Eating During Cancer January 2, 2024 Load more HOT NEWS Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... What’s happened to cancer clinical trials during the COVID-19 pandemic? Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients...
